6EYO

Structure of extended IgE-Fc in complex with two anti-IgE Fabs

Summary for 6EYO

• Entry DOI: 10.2210/pdb6eyo/pdb
• Descriptor: Immunoglobulin heavy constant epsilon, 8D6 Fab heavy chain, 8D6 Fab light chain, ... (5 entities in total)
• Functional Keywords: immunoglobulin e, fab, antibody, complex, immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 6
• Total formula weight: 171734.64

Authors

Chen, J.B.,Ramadani, F.,Pang, M.O.Y.,Beavil, R.L.,Holdom, M.D.,Mitropoulou, A.N.,Beavil, A.J.,Gould, H.J.,Chang, T.W.,Sutton, B.J.,McDonnell, J.M.,Davies, A.M. (deposition date: 2017-11-13, release date: 2018-08-15, Last modification date: 2024-11-13)

Primary citation

Chen, J.B.,Ramadani, F.,Pang, M.O.Y.,Beavil, R.L.,Holdom, M.D.,Mitropoulou, A.N.,Beavil, A.J.,Gould, H.J.,Chang, T.W.,Sutton, B.J.,McDonnell, J.M.,Davies, A.M.
Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody.
Sci Rep, 8:11548-11548, 2018

PubMed Abstract: Immunoglobulin E (IgE) antibodies play a central role in the allergic response: interaction with FcεRI on mast cells and basophils leads to immediate hypersensitivity reactions upon allergen challenge, while interaction with CD23/FcεRII, expressed on a variety of cells, regulates IgE synthesis among other activities. The receptor-binding IgE-Fc region has recently been found to display remarkable flexibility, from acutely bent to extended conformations, with allosteric communication between the distant FcεRI and CD23 binding sites. We report the structure of an anti-IgE antibody Fab (8D6) bound to IgE-Fc through a mixed protein-carbohydrate epitope, revealing further flexibility and a novel extended conformation with potential relevance to that of membrane-bound IgE in the B cell receptor for antigen. Unlike the earlier, clinically approved anti-IgE antibody omalizumab, 8D6 inhibits binding to FcεRI but not CD23; the structure reveals how this discrimination is achieved through both orthosteric and allosteric mechanisms, supporting therapeutic strategies that retain the benefits of CD23 binding.

PubMed: 30069035
DOI: 10.1038/s41598-018-29664-4

Experimental method

X-RAY DIFFRACTION (3.7 Å)